MDPI and ACS Style
Fallacara, A.L.; Zamperini, C.; Podolski-Renić, A.; Dinić, J.; Stanković, T.; Stepanović, M.; Mancini, A.; Rango, E.; Iovenitti, G.; Molinari, A.;
et al. A New Strategy for Glioblastoma Treatment: In Vitro and In Vivo Preclinical Characterization of Si306, a Pyrazolo[3,4-d]Pyrimidine Dual Src/P-Glycoprotein Inhibitor. Cancers 2019, 11, 848.
https://doi.org/10.3390/cancers11060848
AMA Style
Fallacara AL, Zamperini C, Podolski-Renić A, Dinić J, Stanković T, Stepanović M, Mancini A, Rango E, Iovenitti G, Molinari A,
et al. A New Strategy for Glioblastoma Treatment: In Vitro and In Vivo Preclinical Characterization of Si306, a Pyrazolo[3,4-d]Pyrimidine Dual Src/P-Glycoprotein Inhibitor. Cancers. 2019; 11(6):848.
https://doi.org/10.3390/cancers11060848
Chicago/Turabian Style
Fallacara, Anna Lucia, Claudio Zamperini, Ana Podolski-Renić, Jelena Dinić, Tijana Stanković, Marija Stepanović, Arianna Mancini, Enrico Rango, Giulia Iovenitti, Alessio Molinari,
and et al. 2019. "A New Strategy for Glioblastoma Treatment: In Vitro and In Vivo Preclinical Characterization of Si306, a Pyrazolo[3,4-d]Pyrimidine Dual Src/P-Glycoprotein Inhibitor" Cancers 11, no. 6: 848.
https://doi.org/10.3390/cancers11060848